Breast cancer remains the most common cancer diagnosed in women worldwide, with around 2.3 million new cases and 670,000 deaths reported in 2022. The World Health Organization projects that breast cancer incidence and mortality may increase by about 40% by 2050, especially in regions with limited healthcare resources.
However, it’s not just the traditional form of breast cancer that poses a threat. Invasive lobular carcinoma (ILC), a lesser-known subtype, is quietly increasing in the United States. This year, about 33,600 new ILC cases are expected, with an annual rise of 2.8% from 2012 to 2021—much faster than other breast cancers.
Unlike invasive ductal carcinoma (IDC), which forms firm tumors in breast ducts, ILC originates in the milk-producing lobules and often grows diffusely. This makes ILC harder to detect early, frequently contributing to later diagnoses and slower treatment responses. Moreover, ILC’s long-term outcomes may be poorer than IDC once the disease advances or metastasizes.
Several factors may be driving the rise in ILC cases, including:
- Limitations in traditional mammograms to detect diffuse ILC growth, though improved imaging like MRI is helping.
- Hormonal exposures and longer-term estrogen influence, linked to hormone receptor-positive tumors.
- Aging populations and increased use of menopausal hormone therapy.
- Genetic variants (e.g., CDH1 mutations) that increase lobular cancer risk.
- Lifestyle factors such as obesity, alcohol use, delayed childbirth, and fewer pregnancies.
Early warning signs of ILC can be subtle and may not include a distinct lump. Symptoms to watch for include:
- Breast thickening or fullness rather than a firm mass
- Changes in breast size or shape, often without pain
- Skin texture changes such as dimpling or an “orange peel” appearance
- Nipple inversion or retraction
- Nipple discharge, sometimes bloody or watery
- Persistent mild breast discomfort or ache
- Swollen lymph nodes near the armpit or collarbone
Because these signs are often mild or mistaken for benign conditions, clinicians emphasize the need for increased awareness and improved screening methods. Diagnosing ILC typically requires advanced imaging and biopsy, as about one in six breast cancers may not present with a palpable lump.
Related topics
95% of Women in Menopause Lack Access to Effective Treatment
Free PCOS Screening Launches in New Partnership to Boost Awareness
Menopause Supplements Surge: New Formulas Target Symptoms and Health
